On Monday, Lineage Cell Therapeutics Inc (AMEX: LCTX) opened higher 3.88% from the last session, before settling in for the closing price of $1.03. Price fluctuations for LCTX have ranged from $0.37 to $1.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.93% annually for the last half of the decade. Company’s average yearly earnings per share was noted -9.73% at the time writing. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
In an organization with 77 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.15%, operating margin of -223.1%, and the pretax margin is -169.12%.
Lineage Cell Therapeutics Inc (LCTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 48.58%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -9.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.01% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Check out the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). In the past quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.51 million. That was inferior than the volume of 1.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 75.77%.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 89.81%, which indicates a significant increase from 73.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1102 in the past 14 days, which was higher than the 0.0570 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7325, while its 200-day Moving Average is $0.6623. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $1.1227. Second resistance stands at $1.1754. The third major resistance level sits at $1.2308. If the price goes on to break the first support level at $1.0146, it is likely to go to the next support level at $0.9592. Assuming the price breaks the second support level, the third support level stands at $0.9065.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
There are currently 228,356K shares outstanding in the company with a market cap of 244.34 million. Presently, the company’s annual sales total 9,500 K according to its annual income of -18,610 K. Last quarter, the company’s sales amounted to 1,500 K and its income totaled -4,140 K.
